Quality-adjusted time without symptoms of disease progression or toxicity (Q-TWiST) of nivolumab plus cabozantinib (N+C) versus sunitinib (SUN) in treatment-naïve, advanced/metastatic renal cell carcinoma (aRCC): A post-hoc analysis of CheckMate 9ER (CM 9ER) data.

David Cella,Robert J. Motzer,Jessica May,Joel Wallace,Florence Marteau,YoungMin Kwon,Nifasha Rusibamayila,Marc F. Botteman,Flavia Ejzykowicz,Toni K. Choueiri

Quality-adjusted time without symptoms of disease progression or toxicity (Q-TWiST) of nivolumab plus cabozantinib (N+C) versus sunitinib (SUN) in treatment-naïve, advanced/metastatic renal cell carcinoma (aRCC): A post-hoc analysis of CheckMate 9ER (CM 9ER) data.

2021

David Cella
Robert J. Motzer
Jessica May
Joel Wallace
Florence Marteau
YoungMin Kwon
Nifasha Rusibamayila
Marc F. Botteman
Flavia Ejzykowicz
Toni K. Choueiri

6567Background: In CM 9ER (ClinicalTrial.gov identifier NCT03141177), N+C demonstrated significant progression-free survival gains (median: 17.0 vs. 8.3 months [mos]; hazard ratio [HR]: 0.52; P <.0...

Keywords:

Hazard ratio
Nivolumab
Medicine
Renal cell carcinoma
Cabozantinib
Toxicity
Post-hoc analysis
Sunitinib
Checkmate
Urology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations